Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Targeted Cancer Therapies

Targeted Cancer Therapies

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Cancer Therapies

Cancer Therapies

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The peripheral immune landscape of human breast cancer.

Oncoimmunology·2026

Same author

Minimally Invasive Orthopaedic Surgical Techniques: Comparative Effectiveness, Complication Rates, and Patient Outcomes in a Systematic Review and Meta-Analysis.

Cureus·2026

Same author

The immunology of human breast cancer.

Nature reviews. Immunology·2026

Same author

Heparan Sulphate Glycosaminoglycan Chains Contribute to the Tethering of Coronal Factors and Are Important for Extracellular Vesicle-Mediated Fibroblast Activation.

Journal of extracellular biology·2026

Same author

Unravelling nanoscale chemistries in complex biological systems using photoinduced force microscopy (PiFM).

Faraday discussions·2026

Same author

Comment on "Identification of the molecular characterization and tumor microenvironment of thoracic inflammatory myofibroblastic tumors".

Journal of the Formosan Medical Association = Taiwan yi zhi·2026

Search research articles

Related Experiment Video

Updated: Apr 19, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Classification of current anticancer immunotherapies.

Lorenzo Galluzzi¹, Erika Vacchelli², José-Manuel Bravo-San Pedro²

¹Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Gustave Roussy Cancer Campus, Villejuif, France. Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France.

|December 25, 2014

Summary

This summary is machine-generated.

Anticancer immunotherapy has advanced significantly. This study proposes a new classification system for immunotherapies based on antigen specificity, offering a clearer understanding of their clinical applications.

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Related Experiment Videos

Last Updated: Apr 19, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Area of Science:

Oncology
Immunology
Pharmacology

Background:

Anticancer immunotherapy has transitioned from experimental to a clinically validated treatment modality.
Numerous immunotherapeutic agents are approved or under investigation, used alone or in combination with conventional therapies.
Current classifications of immunotherapy (e.g., passive vs. active) do not fully capture the intricate drug-host-tumor interactions.

Purpose of the Study:

To propose a novel, integrated classification system for anticancer immunotherapies.
To critically evaluate existing and emerging immunotherapeutic strategies.
To discuss the clinical significance of a refined classification framework.

Main Methods:

Review and analysis of current literature on anticancer immunotherapies.
Development of a new classification scheme based on antigen specificity.
Evaluation of the clinical relevance and implications of the proposed classification.

Main Results:

Identified limitations in current immunotherapy classification systems.
Proposed a classification based on antigen specificity (single/few vs. broad/unknown).
Highlighted the clinical relevance of understanding immunotherapy mechanisms and specificity.

Conclusions:

A refined classification of anticancer immunotherapies is crucial for understanding their clinical efficacy.
Antigen specificity offers a more insightful framework for categorizing immunotherapeutic approaches.
This integrated classification aids in optimizing treatment strategies and future drug development.